title: Serotonergic blockade compared with beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin with propranolol.
abstract: The safety and efficacy of ketanserin, a competitive serotonin blocking agent, and propranolol were compared in 33 patients with mild to moderate hypertension (sitting diastolic blood pressure [DBP] 95-115 mm Hg) using a placebo run-in, randomized, double-blind parallel study design. All patients received placebo for 4 weeks, then were randomized to receive increasing doses of either ketanserin (20, 40 mg twice daily) or propranolol (40, 80 mg twice daily) to achieve a goal sitting DBP less than 90 mm Hg. Patients not achieving the goal blood pressure with either drug as monotherapy, received the other drug in combination. At the end of the active monotherapy phase (week 10 of the study), propranolol demonstrated a greater decrease in DBP from baseline, as compared to ketanserin (-7.9 +/- 10.9 mm Hg with propranolol, P less than 0.05; -1.0 +/- 7.2 mm Hg with ketanserin, P = NS). Four out of 16 patients achieved goal response on propranolol, compared to 3/17 for ketanserin. With combination treatment, 9/18 patients reached the goal response; the addition of propranolol to ketanserin in non-responders resulted in further reduction of sitting DBP of -10.3 +/- 6.3 compared to monotherapy (P less than 0.001), while the addition of ketanserin to non-responders produced no significant response in sitting DBP. Propranolol showed a consistent effect in slowing heart rate. Ketanserin displayed less frequent side effects than propranolol. Propranolol used twice daily appears to be more effective than twice daily ketanserin use in patients with mild to moderate hypertension.
authors.affiliation: Department of Medicine, the Albert Einstein College of Medicine, Bronx, New York.
authors.forename: S
authors.initials: S
authors.lastname: Okin
authors.forename: S I
authors.initials: SI
authors.lastname: Huberfeld
authors.forename: W H
authors.initials: WH
authors.lastname: Frishman
authors.forename: J
authors.initials: J
authors.lastname: Soberman
authors.forename: L
authors.initials: L
authors.lastname: Laifer
authors.forename: S
authors.initials: S
authors.lastname: Greenberg
authors.forename: J
authors.initials: J
authors.lastname: Lapsker
authors.forename: S
authors.initials: S
authors.lastname: Charlap
authors.forename: J A
authors.initials: JA
authors.lastname: Strom
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007650:Ketanserin / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011897:Random Allocation; D012702:Serotonin Antagonists / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D012702:Serotonin Antagonists; D007650:Ketanserin; D011433:Propranolol